| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10895574 | Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2014 | 7 Pages |
Abstract
The mammalian target of rapamycin (mTOR) pathway regulates cell growth and survival. Alterations in mTOR signaling have been associated with pathological malignancies, including bone metastatic cancer. Inhibition of mTOR signaling might therefore be a promising alternative for bone metastatic cancer management. This review summarizes the current knowledge on mTOR pathway signaling in bone tissue and provides an overview on the known effects of mTOR inhibition in bone cancer, both in in vitro and in vivo models.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Francesco Bertoldo, Franco Silvestris, Toni Ibrahim, Francesco Cognetti, Daniele Generali, Carla Ida Ripamonti, Dino Amadori, Marco Angelo Colleoni, Pierfranco Conte, Lucia Del Mastro, Sabino De Placido, Cinzia Ortega, Daniele Santini,